guest ::
| Home > Publications database > Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. > print |
| Home > Publications database > Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. > print |
| 001 | 182834 | ||
| 005 | 20240229145732.0 | ||
| 024 | 7 | _ | |a 10.1016/j.vaccine.2022.11.044 |2 doi |
| 024 | 7 | _ | |a pmid:36446654 |2 pmid |
| 024 | 7 | _ | |a 0264-410X |2 ISSN |
| 024 | 7 | _ | |a 1358-8745 |2 ISSN |
| 024 | 7 | _ | |a 1873-2518 |2 ISSN |
| 024 | 7 | _ | |a altmetric:139511725 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02961 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Joshi, Smita |b 0 |
| 245 | _ | _ | |a Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. |
| 260 | _ | _ | |a Amsterdam |c 2023 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1677577839_27831 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 41, Issue 1, 4 January 2023, Pages 236-245 |
| 520 | _ | _ | |a The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income countries to introduce the vaccine. From a programmatic perspective the durability of protection offered by a single-dose will be a key consideration. The primary objectives of the present study were to determine whether recipients of a single-dose of quadrivalent HPV vaccine had sustained immune response against targeted HPV types (HPV 6,11,16,18) at 10 years post-vaccination and whether this response was superior to the natural antibody titres observed in unvaccinated women.Participants received at age 10-18 years either one, two or three doses of the quadrivalent HPV vaccine. Serology samples were obtained at different timepoints up to 10 years after vaccination from a convenience sample of vaccinated participants and from age-matched unvaccinated women at one timepoint. The evolution of the binding and neutralizing antibody response was presented by dose received. 10-year durability of immune responses induced by a single-dose was compared to that after three doses of the vaccine and in unvaccinated married women.The dynamics of antibody response among the single-dose recipients observed over 120 months show stabilized levels 18 months after vaccination for all four HPV types. Although the HPV type-specific (binding or neutralizing) antibody titres after a single-dose were significantly inferior to those after three doses of the vaccine (lower bounds of GMT ratios < 0.5), they were all significantly higher than those observed in unvaccinated women following natural infections (GMT ratios: 2.05 to 4.04-fold higher). The results correlate well with the high vaccine efficacy of single-dose against persistent HPV 16/18 infections reported by us earlier at 10-years post-vaccination.Our study demonstrates the high and durable immune response in single-dose recipients of HPV vaccine at 10-years post vaccination. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Human papillomavirus |2 Other |
| 650 | _ | 7 | |a Natural immunity |2 Other |
| 650 | _ | 7 | |a Single dose |2 Other |
| 650 | _ | 7 | |a Vaccine immune responses |2 Other |
| 650 | _ | 7 | |a quadrivalent HPV vaccine |2 Other |
| 700 | 1 | _ | |a Anantharaman, Devasena |b 1 |
| 700 | 1 | _ | |a Muwonge, Richard |b 2 |
| 700 | 1 | _ | |a Bhatla, Neerja |b 3 |
| 700 | 1 | _ | |a Panicker, Gitika |b 4 |
| 700 | 1 | _ | |a Butt, Julia Anna |0 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |b 5 |u dkfz |
| 700 | 1 | _ | |a Rani Reddy Poli, Usha |b 6 |
| 700 | 1 | _ | |a Malvi, Sylla G |b 7 |
| 700 | 1 | _ | |a Esmy, Pulikkottil O |b 8 |
| 700 | 1 | _ | |a Lucas, Eric |b 9 |
| 700 | 1 | _ | |a Verma, Yogesh |b 10 |
| 700 | 1 | _ | |a Shah, Anand |b 11 |
| 700 | 1 | _ | |a Zomawia, Eric |b 12 |
| 700 | 1 | _ | |a Pimple, Sharmila |b 13 |
| 700 | 1 | _ | |a Jayant, Kasturi |b 14 |
| 700 | 1 | _ | |a Hingmire, Sanjay |b 15 |
| 700 | 1 | _ | |a Chiwate, Aruna |b 16 |
| 700 | 1 | _ | |a Divate, Uma |b 17 |
| 700 | 1 | _ | |a Vashist, Shachi |b 18 |
| 700 | 1 | _ | |a Mishra, Gauravi |b 19 |
| 700 | 1 | _ | |a Jadhav, Radhika |b 20 |
| 700 | 1 | _ | |a Siddiqi, Maqsood |b 21 |
| 700 | 1 | _ | |a Sankaran, Subha |b 22 |
| 700 | 1 | _ | |a Pillai Rameshwari Ammal Kannan, Thiraviam |b 23 |
| 700 | 1 | _ | |a Kartha, Purnima |b 24 |
| 700 | 1 | _ | |a Shastri, Surendra S |b 25 |
| 700 | 1 | _ | |a Sauvaget, Catherine |b 26 |
| 700 | 1 | _ | |a Radhakrishna Pillai, M. |b 27 |
| 700 | 1 | _ | |a Waterboer, Tim |0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |b 28 |u dkfz |
| 700 | 1 | _ | |a Müller, Martin |0 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579 |b 29 |u dkfz |
| 700 | 1 | _ | |a Sehr, Peter |0 P:(DE-He78)219d54a7bf634121fbf16bea82d434e1 |b 30 |u dkfz |
| 700 | 1 | _ | |a Unger, Elizabeth R |b 31 |
| 700 | 1 | _ | |a Sankaranarayanan, Rengaswamy |b 32 |
| 700 | 1 | _ | |a Basu, Partha |b 33 |
| 773 | _ | _ | |a 10.1016/j.vaccine.2022.11.044 |g p. S0264410X22014578 |0 PERI:(DE-600)1468474-3 |n 4 |p 236-245 |t Vaccine |v 1 |y 2023 |x 0264-410X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:182834 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 29 |6 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 30 |6 P:(DE-He78)219d54a7bf634121fbf16bea82d434e1 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b VACCINE : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b VACCINE : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)F020-20160331 |k F020 |l Infektionen und Krebs-Epidemiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)W040-20160331 |k W040 |l Gruppe Sehr EMBL |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)W040-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|